In undertaking this survey, researchers aimed to assess the limitations of ctDNA testing in the clinic, as well as areas in which it is considered clinically meaningful.
Ultrasensitive ctDNA testing distinguishes patients with very different risks for recurrence — but it remains to be seen whether acting on the results can improve their outcomes.
Medpage Today on MSN
ctDNA Testing Shows Promise for Influencing Colorectal Cancer Treatment
SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal ...
Dr. Hua-Jay Cherng, a hematologist oncologist at NewYork-Presbyterian/Columbia University Medical Center, discussed how ctDNA ...
Medindia on MSN
Novel ctDNA blood test to track and treat prostate cancer
India, March 23 -- Advances in cancer research are improving how doctors diagnose and monitor diseases. One emerging tool is ...
New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...
Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...
Please provide your email address to receive an email when new articles are posted on . Approximately 25% of patients had ctDNA- or imaging-confirmed recurrence. More than 30% had evidence of ...
Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma. Circulating tumor DNA (ctDNA) is not yet standard practice in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results